

## Original Investigation

# Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia

## A Meta-analysis

Steven M. Belknap, MD; Imran Aslam, BS; Tina Kiguradze, BS; William H. Temps, Paul R. Yarnold, PhD; John Cashy, PhD; Robert E. Brannigan, MD; Giuseppe Micali, MD; Beatrice Nardone, MD, PhD; Dennis P. West, PhD

**IMPORTANCE** Two meta-analyses conclude that finasteride treatment of androgenic alopecia (AGA) is safe but do not assess quality of safety reporting.

**OBJECTIVE** To assess safety reporting for clinical trial reports of finasteride for AGA.

**DATA SOURCES** MEDLINE, ClinicalTrials.gov, and a clinical data repository for an academic medical center.

**STUDY SELECTION** Published clinical trial reports for finasteride treatment of AGA.

**DATA EXTRACTION AND SYNTHESIS** For each trial, we assessed quality of adverse event reporting, extracted the number and type of adverse events in treatment and placebo groups, and assessed duration of safety evaluation and adequacy of blinding. Two observers independently extracted the data; differences were resolved by consensus. We assessed generalizability in a large cohort of men prescribed finasteride, 1.25 mg/d or less, by assessing for eligibility in the finasteride-AGA pivotal trials.

**MAIN OUTCOMES AND MEASURES** Quality was assessed as adequate, partially adequate, inadequate, or no events reported. We used funnel plots of the hazard ratio to assess bias.

**RESULTS** Of 34 clinical trials, none had adequate safety reporting, 19 were partially adequate, 12 were inadequate, and 3 reported no adverse events. Funnel plots were asymmetric with a bias toward lower odds ratio for sexual adverse effects, suggesting systematic underdetection. No reports assessed adequacy of blinding, 18 (53%) disclosed conflicts of interest, and 19 (56%) received funding from the manufacturer. Duration of drug safety evaluation was 1 year or less for 26 of 34 trials (76%). Of 5704 men in the clinical data repository who were treated for AGA with finasteride, 1.25 mg/d or less, for AGA, only 31% met inclusion criteria for the pivotal trials referenced in the manufacturer's full prescribing information and 33% took finasteride for more than 1 year.

**CONCLUSIONS AND RELEVANCE** Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of AGA, most would have been excluded from the pivotal studies that supported US Food and Drug Administration approval for AGA. Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of AGA.

*JAMA Dermatol.* 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36  
Published online April 1, 2015.

← Editorial page 585

+ Author Audio Interview at  
jamadermatology.com

**Author Affiliations:** Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Belknap, Aslam, Kiguradze, Temps, Nardone, West); Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Belknap, Cashy); Optimal Data Analysis LLC, Evanston, Illinois (Yarnold); Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Cashy, Brannigan); Department of Dermatology, University of Catania, Catania, Italy (Micali).

**Corresponding Author:** Steven M. Belknap, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine, 680 N Lake Shore Dr, Chicago, IL 60611 (sbelknap@northwestern.edu).

Androgenic alopecia (AGA) is characterized by vertex balding of the scalp and recession of the temporal hairline due to 5 $\alpha$ -dihydrotestosterone (5 $\alpha$ -DHT)-dependent miniaturization of hair follicles. About 70% of men develop AGA. Some men with AGA experience adverse psychosocial effects and reduced quality of life, particularly those with early age at onset.<sup>1</sup> The development of finasteride for clinical use was prompted by the observation that male pseudohermaphrodites do not develop prostatic hyperplasia or AGA.<sup>2</sup> Male pseudohermaphrodites have a mutation of the gene encoding 5 $\alpha$ -reductase 2, a global defect in C<sub>19</sub> and C<sub>21</sub> 5 $\alpha$ -metabolism,<sup>3,4</sup> impaired conversion of testosterone to 5 $\alpha$ -DHT, and a reduced 5 $\alpha$ -DHT:testosterone ratio—with varying degrees of genital ambiguity at birth.<sup>2,5</sup> Pseudohermaphrodites are often raised as girls but unexpectedly virilize at puberty, with partial masculinization of external genitalia.<sup>2</sup> Finasteride is a 5 $\alpha$ -reductase inhibitor that reduces serum 5 $\alpha$ -DHT by 70% at doses of either 1 mg or 5 mg,<sup>6,7</sup> inducing a sex steroid profile “strikingly similar to that of pseudohermaphrodites.”<sup>8(p777)</sup> Implicit in the use of finasteride is the assumption that inhibiting formation of 5 $\alpha$ -DHT will not interfere with maintenance of the structure or function of male reproductive organs, despite the expression of 5 $\alpha$ -reductase 2 in these organs<sup>9</sup> and despite the overexpression of nuclear androgen receptor in men with persistent sexual dysfunction after discontinuation of finasteride.<sup>10</sup>

One meta-analysis of controlled trials of finasteride for AGA found “no significant difference between active treatment and placebo for the outcome global sexual disturbance”<sup>11(p160)</sup> and asserted that “controlled-clinical trial data shows a low incidence of sexual side effects that resolve on treatment.”<sup>11(p160)</sup> A second meta-analysis found that, “the only adverse effect that was significantly more frequent with finasteride therapy in comparison to placebo treatment was erectile dysfunction”<sup>12(p1149)</sup> and that only “1 of every 80 patients treated will experience erectile dysfunction.”<sup>12(p1149)</sup> Neither analysis assesses the quality of adverse event reporting nor evaluates generalizability to clinical practice. Recent reports describe that impotence, loss of libido,<sup>13,14</sup> low androgen levels, and severe oligospermia<sup>15</sup> may persist long after discontinuation of finasteride at a dosage of 1.25 mg/d or less. Yet, a medical literature review of the use of finasteride for AGA concludes that finasteride is safe for AGA and notes that “permanent sexual adverse events have yet to be established in higher quality studies, such as randomized controlled trials.”<sup>16(p493)</sup> Although clinical trial reports are generally considered the best source of information about the efficacy and safety of drug therapy, a recent meta-analysis found that 35% of published reanalyses of clinical trial data made conclusions that were different from those in the original published report.<sup>17</sup> Accordingly, we evaluated the quality and relevance of adverse event reporting for published clinical trials of finasteride for AGA.

## Methods

We searched Medline for reports of clinical trials of oral finasteride for treatment of AGA in men using the keywords “alo-

pecia,” “androgenic alopecia,” “5 $\alpha$ -reductase inhibitor,” “finasteride,” and “Propecia,” identified 353 items, and manually assessed each item for content, relevance, and duplication, yielding 34 unique clinical trial reports.<sup>6,7,18-49</sup> We searched ClinicalTrials.gov using the keyword “finasteride” and found no nonduplicative reports. We evaluated each of the 34 reports of finasteride AGA trials for study design, drug dosage, sample size, average age, study duration, quality of adverse event reporting, adequacy of blinding, treatment indication, withdrawal rate, inclusion and exclusion criteria, conflicts of interest, and funding source. We determined odds ratios for sexual dysfunction, decreased libido, and impotence for those studies with both a finasteride arm and a placebo arm for which the requisite information was available. Two observers (I.A. and T.K.) independently extracted the data; differences were resolved by consensus.

We classified adequacy of blinding as “not applicable” for studies with 1 arm, as “yes” for studies reporting assessment of adequacy of blinding, and as “unknown” for those not reporting assessment of adequacy of blinding. We scored drug safety reporting for each report using the adverse event reporting quality scale of Ioannidis and Lau<sup>50</sup> as “adequate,” “partially adequate,” or “inadequate.” Reports that explicitly stated that no adverse events had occurred were scored as “none.” Trials were classified as having adequate quality of adverse event reporting if they used an explicit toxicity scale to grade adverse event severity and reported numbers and/or rates of occurrence for each specific type of adverse event per study arm. Trials were classified as having partially adequate quality of adverse event reporting if they failed to distinguish reports of severe toxicity from reports of moderate toxicity or otherwise did not meet criteria for the adequate or inadequate categories. Trials were classified as having inadequate quality of adverse event reporting if they did not enumerate specific types of adverse events, provided only generic statements, or omitted comment entirely.

To assess generalizability, we evaluated eligibility for the 3 manufacturer-sponsored trials<sup>26,27,32</sup> referenced in the Clinical Studies section of the full prescribing information for finasteride, 1 mg, using as our data source the Northwestern University Enterprise Data Warehouse, a clinical data repository of ambulatory and hospitalized patients, providing laboratory data and diagnosis codes from 1992 through 2013 and comprehensive electronic medical record data from January 2001 through September 2013. We applied a 1.25-mg dose threshold because tablet splitting of the 5-mg dose was widely used as a cost-saving measure. We identified all *International Classification of Diseases, Ninth Revision (ICD-9)* codes for the cohort of men prescribed finasteride, 1.25 mg/d or less, in the clinical data repository and identified 345 exclusionary ICD-9 codes based on the exclusion criteria for the 3 trials<sup>26,27,32</sup> referenced in the full prescribing information for men younger than 42 years. Principal exclusion criteria included significant abnormalities on screening physical examination or laboratory evaluation.<sup>26,27</sup>

The Northwestern University institutional review board granted approval for conduct of this study.

Table 1. Comprehensive List of Clinical Trials That Used Finasteride in Treatment of Men With Androgenic Alopecia<sup>a</sup>

Source	Patients, Total No.	Patients Presc Finasteride, No.	Age, Mean, y	Duration, wk	Dose, mg	Quality	Adequacy Concealment	Withdrawal Rate	COI, Y/N/U	Funding	Inclusion/Exclusion Criteria
Gubelin-Harcha et al <sup>24</sup>	917	179	38	24	1	Part	U	0.02	Y	GSK	Testosterone level <250 ng/dL, unstable liver disease
Sato and Takeda <sup>44</sup>	3177	3177	37.5	182	1	Part	NA	0.007	U	U	Unknown
Motofei et al <sup>34</sup>	33	33	36.5	4	1	Part	NA	U	N	U	Free of general disease, patients with significant comorbidities being excluded
Rossi et al <sup>42</sup>	100	50	U	104	1	Inad	U	0	N	U	Ages 20-40 y, in good health; no significant abnormalities on physical exam
Olsen et al <sup>36</sup>	424	286	45	104	1	Inad	U	U	Y	Merck	No significant abnormalities on screening physical exam or lab eval
Rossi et al <sup>41</sup>	118	118	U	520	1	Part	NA	0.04	N	None	Good physical and mental health, no significant abnormalities on screening physical exam
Yamazaki et al <sup>49</sup>	27	27	33.8	24	1	Inad	NA	U	U	U	U
Duskova et al <sup>23</sup>	12	12	28.8	52	1	Inad	NA	0	U	Govt grant	U
Hajheydari et al <sup>25</sup>	45	19	22.8	24	1	Part	U	0.16	N	Univ grant	Complete physical and psychological health
Kaufman et al <sup>28</sup>	1553	645	33	52	1	Part	U	0.012	Y	Merck	No significant abnormalities on screening physical exam or lab eval, ages 18-41 y
Camacho et al <sup>20</sup>	270	270	14-58	52	1	Inad	NA	U	N	U	Patients with I/II HN were not included in the study
D'Amico and Roehrborn <sup>21</sup>	355	285	40-60	48	1	Inad	U	0.042	N	Merck	Ambulatory and in good general physical and mental health. No history of thyroid disease, abnormal LFTs, or any condition that, in the opinion of investigators, might confound results
Olsen et al <sup>35</sup>	416	70	36.4	24	5	Part	U	0	Y	GSK	No significant health problems
Rahimi-Ardabili et al <sup>40</sup>	128	128	25.8	8	1	Part	NA	0	N	U	History of mood disorder or any chronic disease <sup>b</sup>
Price et al <sup>38</sup>	66	15	22-40	192	1	Part	U	0	Y	Merck	Good physical and mental health
Ryu et al <sup>43</sup>	21	21	31.3	20	1	Inad	NA	U	N	Korean govt grant	Healthy, ages 23-52 y
Leavitt et al <sup>31</sup>	79	40	40	52	1	Inad	U	0.15	Y	Merck	Healthy, ages 20-45 y, no clinically significant abnormalities in the medical history or on screening physical
Kawashima et al <sup>29</sup>	414	139	40	48	1	Part	U	U	Y	Banyu Pharm	Good physical and mental health; no history of or ongoing thyroid disease or presence of elevated LFTs
Arca et al <sup>18</sup>	65	40	27.5	52	1	Part	U	0	U	U	Good health <sup>c</sup>
Whiting et al <sup>47</sup>	424	286	49.9	104	1	Part	U	0.056	U	U	Patients excluded from study if they had alopecia due to causes other than MPHL
Lin and Chen <sup>33</sup>	34	34	28.8	24	1	None	NA	0	U	U	No significant abnormalities on screening physical exam or lab eval

(continued)

Table 1. Comprehensive List of Clinical Trials That Used Finasteride in Treatment of Men With Androgenic Alopecia<sup>a</sup> (continued)

Source	Patients, Total No.	Patients Presc Finasteride, No.	Age, Mean, y	Duration, wk	Dose, mg	Quality	Adequacy Concealment	Withdrawal Rate	COI, Y/N/U	Funding	Inclusion/Exclusion Criteria
Khandpur et al <sup>30</sup>	100	31	24.86	52	1	Part	U	U	U	U	No patients with HTN (BP>140/90 mm Hg), or history of cardiac, renal, hepatic, endocrine, or psychiatric disorder
Price et al <sup>39</sup>	66	66	33	48	1	Part	U	0	Y	Merck	Good physical and mental health, no significant abnormalities on screening physical exam or lab eval
Kaufman et al <sup>26,d</sup>	1553	323	33	260	1	Part	U	0.006	Y	Merck	No significant abnormalities on screening, physical exam or lab eval, ages 18-41 y
Stough et al <sup>45</sup>	18	9	38.6	52	1	None	U	0	Y	Merck	No history of any significant illness that may confound the results of the study
Van Neste et al <sup>46</sup>	212	106	30.2	48	1	Inad	U	U	Y	Merck	Good physical and mental health, no significant abnormalities on screening physical exam or lab eval
Whiting et al <sup>48</sup>	26	14	18-41	52	1	Inad	U	U	Y	Merck	U
Roberts et al <sup>7</sup>	466	117	30	24	1 and 5	Part	U	0.034	Y	Merck	Healthy, ages 18-36 y
Drake et al <sup>6</sup>	249	37	36	6	1 and 5	Part	U	U	Y	Merck	Good health, ages 18-50 y
Overstreet et al <sup>37</sup>	181	91	30.3	48	1	Inad	U	0	Y	Merck	Excellent general health determined by medical history, physical exam, and screening lab testing
Leyden et al <sup>32,d</sup>	326	166	33	52	1	Part	U	0	Y	Merck	Good physical and mental health, ages 18-40 y
Kaufman et al <sup>27,d</sup>	1553	471	33	52	1	Part	U	0.015	Y	Merck	No significant abnormalities on screening physical exam or lab eval
Brenner and Matz <sup>19</sup>	28	28	53-76	104	5	None	U	U	U	U	U
Dallob et al <sup>22</sup>	17	8	30-55	4	5	Inad	U	U	Y	Merck	Healthy, ages 30-55 y

Abbreviations: BP, blood pressure; COI, conflict of interest; eval, evaluation; exam, examination; govt, government; GSK, GlaxoSmithKline; HN, Hamilton-Norwood score; HTN, hypertension; inad, inadequate quality; lab, laboratory; LFT, liver function test; MPHL, male pattern hair loss; N, no; NA, not applicable; part, partially adequate; presc, prescribed; quality, quality of adverse event reporting; U, unknown; univ, university; Y, yes.

<sup>a</sup> The total number of 9751 patients is less than that obtained by adding up the study cohort sizes because some information is reported in multiple reports. Also, some cohorts are assessed on multiple occasions. Kaufman et al,<sup>26-28</sup> Olsen et al,<sup>36</sup> and Whiting et al<sup>48</sup> refer to the same clinical trial. Rossi et al<sup>42</sup>

is a follow-up of the same cohort as reported in Rossi et al.<sup>41</sup> Similarly, Price et al<sup>38</sup> is a follow-up of Price et al.<sup>39</sup>

<sup>b</sup> Especially diseases associated with behavioral changes (eg, diabetes mellitus, hypothyroidism and asthma) were excluded from the study, as were using other medications at the beginning of treatment.

<sup>c</sup> Cardiac, psychiatric, or scalp disease were excluded if patient was prescribed any systemic drug, egsteroids, antihypertensive drug, or  $\beta$ -blockers.


<sup>d</sup> Clinical trials referenced in manufacturer's full prescribing information.

## Results

Of 34 articles, none had adequate safety reporting, 19 (56%) had partially adequate reporting, 12 (35%) had inadequate safety reporting, and 3 (9%) reported that no adverse events occurred (Table 1). Of 25 clinical trial reports with a control arm, none reported on adequacy of blinding. The 34 publications reported data for 9751 unique human participants: 18 articles (53%) disclosed that authors had conflicts of interest, 19 articles (56%) reported funding by a pharmaceutical manufacturer of finasteride, and 12 articles (35%) did not dis-

close a funding source; 26 trials (76%) had a study duration of 1 year or less. The median number of participants assigned to a finasteride treatment arm was 68 (range, 8-3177 participants); 29 trials evaluated a finasteride dose of 1 mg, 2 studies evaluated doses of both 1 and 5 mg, and 3 studies evaluated a dose of 5 mg. The mean age of participants was 35.5 years across all studies. Nonsexual adverse drug events were not reported in 28 articles. One report<sup>40</sup> specifically evaluated depression, finding a clinically and statistically significant increase in Beck Depression Inventory Scores after exposure to finasteride, but did not adequately assess adverse effects other than depression. Another 5 studies<sup>7,27,33,35,44</sup> reported

Figure. Funnel Plots of Sexual Adverse Drug Events for Finasteride to Placebo Ratio in Controlled Clinical Trials of Finasteride for Androgenic Alopecia



Funnel plots of odds ratio (OR) (horizontal axis) vs sample size (vertical axis) for all unique evaluations for those studies that either explicitly reported an OR or that provided enough information to calculate ORs. A, Sexual dysfunction. B, Impotence. C, Libido. See Results section.

nonsexual adverse drug events, including increased body hair, gynecomastia, elevated liver function tests, elevated cholesterol levels, and mood disorder.

Sufficient information was available to calculate an odds ratio of sexual dysfunction for 7 studies<sup>7,26,29,32,37,46,47</sup> (21%), of decreased libido for 12 studies\* (35%), and of impotence for 7 studies<sup>7,24,26,27,32,35,47</sup> (24%). The Figure shows funnel plots of odds ratios vs sample size of the finasteride arm for these outcomes. All 3 funnel plots are asymmetric with a bias toward lower odds ratios, suggesting possible underdetection or underreporting of sexual adverse effects in these trials, perhaps owing to publication bias. Alternatively, the larger clinical trials may have differed systematically from the others.

\*References 6, 7, 18, 24, 26, 27, 29, 31, 32, 35, 39, 47

Of the 5704 men in the clinical data set who were prescribed finasteride at doses of 1.25 mg or less daily, 69% would have been excluded from the clinical trials that supported the new drug application for finasteride, 1 mg (Table 2). Also, while 26 of the 34 clinical trials had a study duration of 1 year or less, 33% of the men in the clinical data repository had more than 1 year of exposure to finasteride, and 12% had more than 3 years of exposure to finasteride.

## Discussion

Of 34 studies, none met the criteria of Ioannidis and Lau<sup>50</sup> for adequate safety reporting. Most provided no description of the

duration or severity of signs or symptoms of sexual dysfunction and failed to distinguish between mild, reversible sexual dysfunction and severe, permanent sexual dysfunction. Also, given that some participants randomized to finasteride would likely have noticed cessation or reversal of balding and that adverse event assessments were based on participant reports, the lack of assessment of adequacy of blinding is a serious flaw in the reporting of these 34 clinical trials. Furthermore, lack of generalizability represents another serious limitation of the available clinical trial data because analysis of a large cohort of men actually taking finasteride at doses of 1.25 mg/d or less per routine care showed that 69% of such men met exclusion criteria for the 3 clinical trials that supported FDA approval of finasteride, 1 mg daily, for AGA.

## Conclusions

Clinical trials provide the "...best (and only) opportunity for assessing the frequency and severity of common side effects from a new medication in a controlled setting."<sup>50(p442)</sup> This opportunity to identify and characterize drug toxicity may be lost when investigators do not use validated, effective methods for detecting adverse events, grading their severity, and evaluating causality. Remarkably, the sole study<sup>40</sup> that used validated methods to assess depression in men found a strong association between finasteride exposure and depression, while only 1 of the remaining 33 trials reports "mood disorder" as an adverse event and determined this to be not significant. Cli-

**Table 2. Population Prescribed Finasteride at 1 Academic Medical Center, 1992 to 2013, Evaluated by Exclusion Criteria for Pivotal Trials<sup>a</sup>**

Condition	Subjects, No. (%)	
	Included	Excluded
Entire cohort	5704 (100)	0
Eligible cohort after application of all exclusion criteria	1775 (31.1)	3929 (68.9)
Age <18 y or age >41 y (as of date of first prescription)	4439 (77.8)	1265 (22.2)
Disorders of male genital organs	4756 (83.4)	948 (16.6)
Anxiety, dissociative, and somatoform disorders	4890 (85.7)	814 (14.3)
Heart disease	4930 (86.4)	774 (13.6)
Hypertensive disease	4944 (86.7)	760 (13.3)
Malignant neoplasms	5218 (91.5)	486 (8.5)
Depressive disorder	5239 (91.8)	465 (8.2)
Asthma	5281 (92.6)	423 (7.4)
Alcohol dependence, drug dependence, or drug abuse	5298 (92.9)	406 (7.1)
Obesity	5446 (95.5)	258 (4.5)
All other exclusions	4799 (84.1)	905 (15.9)

<sup>a</sup> Referenced in manufacturer's full prescribing information for finasteride, 1 mg, oral tablets.

nicians depend on clinical trial reports as the definitive source of information on drug toxicity. One might reasonably expect that 34 studies and 2 meta-analyses would be adequate to establish the rate of finasteride adverse effects in AGA, yet this does not seem to be the case.

## ARTICLE INFORMATION

**Accepted for Publication:** January 14, 2015.

**Published Online:** April 1, 2015.  
doi:10.1001/jamadermatol.2015.36.

**Author Contributions:** Drs Belknap and West had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Belknap, Aslam, Kiguradze, West.

**Acquisition, analysis, or interpretation of data:** Belknap, Aslam, Kiguradze, Cashy, Temps, Yarnold, Brannigan, Micali, Nardone.

**Drafting of the manuscript:** Belknap, Aslam, Kiguradze, Cashy.

**Critical revision of the manuscript for important intellectual content:** Belknap, Aslam, Kiguradze, Temps, Yarnold, Brannigan, Micali, Nardone, West.

**Statistical analysis:** Belknap, Temps, Yarnold, Cashy.

**Obtained funding:** Belknap.

**Administrative, technical, or material support:** Aslam, Kiguradze, Temps, West.

**Study supervision:** Belknap, Micali.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This work was supported by National Institutes of Health grants 5R01CA102713-04 (Drs Belknap and West) and 1R01 CA125077-01A1 (Drs Belknap and West). Additional funding was provided by a gift from the Post-Finasteride Syndrome Foundation.

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; the collection, management, analysis,

and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

## REFERENCES

- Han SH, Byun JW, Lee WS, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. *Ann Dermatol*. 2012;24(3):311-318.
- Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5 $\alpha$ -reductase deficiency in man: an inherited form of male pseudohermaphroditism. *Science*. 1974;186(4170):1213-1215.
- Fisher LK, Kogut MD, Moore RJ, et al. Clinical, endocrinological, and enzymatic characterization of two patients with 5 $\alpha$ -reductase deficiency: evidence that a single enzyme is responsible for the 5 $\alpha$ -reduction of cortisol and testosterone. *J Clin Endocrinol Metab*. 1978;47(3):653-664.
- Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 $\alpha$ -reductase in humans. *Prostate*. 1989;14(1):45-53.
- Sinnecker GH, Hiort O, Dibbelt L, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 $\alpha$ -reductase 2 deficiency. *Am J Med Genet*. 1996;63(1):223-230.
- Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. *J Am Acad Dermatol*. 1999;41(4):550-554.
- Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5 $\alpha$ -reductase inhibitor, in men with male pattern hair loss. *J Am Acad Dermatol*. 1999;41(4):555-563.
- Imperato-McGinley J, Shackleton C, Orlic S, Stoner E. C19 and C21 5 $\beta$ /5 $\alpha$  metabolite ratios in subjects treated with the 5 $\alpha$ -reductase inhibitor finasteride: comparison of male pseudohermaphroditism with inherited 5 $\alpha$ -reductase deficiency. *J Clin Endocrinol Metab*. 1990;70(3):777-782.
- Mahony MC, Swanlund DJ, Billeter M, Roberts KP, Pryor JL. Regional distribution of 5 $\alpha$ -reductase type 1 and type 2 mRNA along the human epididymis. *Fertil Steril*. 1998;69(6):1116-1121.
- Di Loreto C, La Marra F, Mazzon G, Belgrano E, Trombetta C, Causi S. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. *PLoS One*. 2014;9(6):e100237.
- Gupta AK, Charrette A. The efficacy and safety of 5 $\alpha$ -reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. *J Dermatolog Treat*. 2014;25(2):156-161.
- Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. *Arch Dermatol*. 2010;146(10):1141-1150.

13. Irwig MS, Kolkulka S. Persistent sexual side effects of finasteride for male pattern hair loss. *J Sex Med*. 2011;8(6):1747-1753.
14. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? *J Sex Med*. 2012;9(11):2927-2932.
15. Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. *JAMA Dermatol*. 2014;150(12):1361-1363.
16. Yim E, Nole KL, Tosti A. 5 $\alpha$ -Reductase inhibitors in androgenetic alopecia. *Curr Opin Endocrinol Diabetes Obes*. 2014;21(6):493-498.
17. Ebrahim S, Sohani ZN, Montoya L, et al. Reanalyses of randomized clinical trial data. *JAMA*. 2014;312(10):1024-1032.
18. Arca E, Açıköz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. *Dermatology*. 2004;209(2):117-125.
19. Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. *Int J Dermatol*. 1999;38(12):928-930.
20. Camacho FM, García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. *Br J Dermatol*. 2008;158(5):1121-1124.
21. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. *Lancet Oncol*. 2007;8(1):21-25.
22. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 $\alpha$ -reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. *J Clin Endocrinol Metab*. 1994;79(3):703-706.
23. Duskova M, Hill M, Starka L. Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. *Endocr Regul*. 2010;44(1):3-8.
24. Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. *J Am Acad Dermatol*. 2014;70(3):489-498.e3.
25. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. *Indian J Dermatol Venereol Leprol*. 2009;75(1):47-51.
26. Kaufman KD; Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. *Eur J Dermatol*. 2002;12(1):38-49.
27. Kaufman KD, Olsen EA, Whiting D, et al; Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia. *J Am Acad Dermatol*. 1998;39(4 Pt 1):578-589.
28. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). *Eur J Dermatol*. 2008;18(4):400-406.
29. Kawashima M, Hayashi N, Igarashi A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. *Eur J Dermatol*. 2004;14(4):247-254.
30. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. *J Dermatol*. 2002;29(8):489-498.
31. Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. *Dermatol Surg*. 2005;31(10):1268-1276.
32. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. *J Am Acad Dermatol*. 1999;40(6 Pt 1):930-937.
33. Lin JH, Chen WC. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study. *Kaohsiung J Med Sci*. 2002;18(8):379-385.
34. Motofei IG, Rowland DL, Georgescu SR, et al. A pilot study on the sexual side effects of finasteride as related to hand preference for men undergoing treatment of male pattern baldness. *BJU Int*. 2013;111(4 Pt B)(4, pt B):221-226.
35. Olsen EA, Hordinsky M, Whiting D, et al; Dutasteride Alopecia Research Team. The importance of dual 5 $\alpha$ -reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *J Am Acad Dermatol*. 2006;55(6):1014-1023.
36. Olsen EA, Whiting DA, Savin R, et al; Male Pattern Hair Loss Study Group. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. *J Am Acad Dermatol*. 2012;67(3):379-386.
37. Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. *J Urol*. 1999;162(4):1295-1300.
38. Price VH, Meneffee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. *J Am Acad Dermatol*. 2006;55(1):71-74.
39. Price VH, Meneffee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. *J Am Acad Dermatol*. 2002;46(4):517-523.
40. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. *BMC Clin Pharmacol*. 2006;6:7.
41. Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. *Dermatol Ther*. 2011;24(4):455-461.
42. Rossi A, Mari E, Scarno M, et al. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. *Int J Immunopathol Pharmacol*. 2012;25(4):1167-1173.
43. Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. *Br J Dermatol*. 2006;154(4):730-734.
44. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. *J Dermatol*. 2012;39(1):27-32.
45. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. *Eur J Dermatol*. 2002;12(1):32-37.
46. Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. *Br J Dermatol*. 2000;143(4):804-810.
47. Whiting DA, Olsen EA, Savin R, et al; Male Pattern Hair Loss Study Group. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. *Eur J Dermatol*. 2003;13(2):150-160.
48. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. *J Invest Dermatol Symp Proc*. 1999;4(3):282-284.
49. Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R. Oral finasteride improved the quality of life of androgenetic alopecia patients. *J Dermatol*. 2011;38(8):773-777.
50. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. *JAMA*. 2001;285(4):437-443.